What it is
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region rather than in nuclear DNA, which is what makes it interesting to mitochondrial biologists. It was described by Lee, Cohen and colleagues at the University of Southern California in 2015 as part of a small family of mitochondrial-derived peptides. It is detectable in human plasma, and human studies to date have measured circulating levels rather than administered the peptide.
Mechanism of action
Lee et al. (2015) reported that the primary target organ appears to be skeletal muscle, and that the peptide's cellular actions inhibit folate-dependent one-carbon metabolism and the de novo purine biosynthesis tethered to it, which raises AMP-activated protein kinase (AMPK) signaling. AMPK activation is the common thread in the literature: it is the pathway through which the peptide is proposed to shift cells toward glucose uptake and fatty acid oxidation, which is why it is sometimes framed as an exercise-responsive signal. Xing et al. (2026) confirmed AMPK activation in human mesenchymal stromal cells but found that restoring the signaling did not restore cell function, which complicates the simple reading that more AMPK signaling is better.
What it’s most studied for
Most research examines metabolic regulation: diet-induced obesity, insulin sensitivity and glucose handling in mice, with skeletal muscle as the assumed target tissue. A second line of work treats circulating MOTS-c as a biomarker of mitochondrial stress and exercise response in people, including studies that measure how levels shift after a training intervention. A third and newer line asks whether the peptide can be used to rescue cells whose mitochondrial signaling has been degraded, for example stromal cells from donors with obesity, which is where the most informative recent result sits. Longevity framing is common in marketing, but the published aging work is rodent and cell based.
Notable findings
Each finding carries the species or population it was observed in and the dose that study used. Doses are reported as research context, exactly as published. They are not guidance.
AMPK signaling restored, senescence markers raised
Xing et al. (2026) compared adipose-derived mesenchymal stromal cells from 6 donors with obesity and 6 lean donors. Cells from donors with obesity had lower basal MOTS-c expression, and adding the peptide restored intracellular levels and activated AMPK signaling. In the same cells it reduced proliferation and increased expression of the senescence-associated genes p16 and p21 and of TNF-alpha. The authors conclude that restoring mitochondrial metabolic signaling was not sufficient to reverse the dysfunction and may exacerbate senescence and inflammation.
- Dose studied
- 10 micromolar in culture medium, human adipose-derived mesenchymal stromal cells; the authors note this is a pharmacological rather than physiological exposure
[1] Xing L et al. · 2026 · PMID 42324588 ↗
No renal benefit in a mouse model
In the in vivo arm of the same study, Xing et al. (2026) delivered MOTS-c-pretreated stromal cells to mice with renal artery stenosis. The pretreated cells failed to improve renal perfusion, fibrosis or tubular injury, and pretreatment also blunted the reparative efficacy of cells from lean donors. This is a negative result in both directions: it did not rescue impaired cells and it degraded the performance of unimpaired ones.
- Dose studied
- Stromal cells pretreated with 10 micromolar MOTS-c before delivery, mouse renal artery stenosis model
[1] Xing L et al. · 2026 · PMID 42324588 ↗
Exercise response in breast cancer survivors
Dieli-Conwright et al. (2021) measured circulating MOTS-c in 49 breast cancer survivors before and after a 16-week supervised exercise intervention, as a secondary analysis of a randomized trial. Levels rose significantly in Non-Hispanic White participants but not in Hispanic participants. Post-exercise MOTS-c correlated with reductions in fat mass, body weight, HOMA-IR and C-reactive protein, and with increased lean mass. No peptide was administered in this study.
- Dose studied
- None administered; circulating MOTS-c measured before and after 16 weeks of supervised aerobic and resistance exercise (49 breast cancer survivors)
[2] Dieli-Conwright CM et al. · 2021 · PMID 34413391 ↗
Diet-induced obesity in mice
Lee et al. (2015) treated outbred CD-1 mice fed a high-fat diet and reported that treatment prevented diet-induced obesity, along with both age-dependent and high-fat-diet-induced insulin resistance. This is the origin study for the metabolic claims made about the peptide, and its endpoints are weight, glucose homeostasis and hepatic lipid accumulation in mice rather than any clinical outcome.
- Dose studied
- 0.5 mg/kg/day intraperitoneally, outbred CD-1 mice on a high-fat diet
[3] Lee C et al. · 2015 · DOI 10.1016/j.cmet.2015.02.009 ↗
Study quality
No published trial has administered MOTS-c to humans; the human literature measures the peptide as a circulating marker, and the evidence for metabolic effects comes from mice and cultured cells. The 2015 origin study is a well-cited mouse paper from a single group, with glucose and weight endpoints rather than clinical ones. The 2026 mesenchymal stromal cell study is the most rigorous recent work and is largely negative; its authors flag two limits themselves, a 10 micromolar pharmacological exposure well above physiological levels, and a small, homogeneous donor pool of 6 cells per group. The human exercise analysis is small (n=49), was a secondary analysis, and had no attention control group, so the ethnicity difference it reports should be treated as a hypothesis. No safety data in humans receiving the peptide exist to report.
On the research desk
Recent records on MOTS-c from the Alpha Helix research feed, each with its evidence tier and citation.
References
- 1Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflammation and Regeneration. PMID 42324588
- 2Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific Reports. PMID 34413391
- 3The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. DOI 10.1016/j.cmet.2015.02.009
- 4July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: votes on nominated bulk drug substances for the 503A list. U.S. Food and Drug Administration.
Free guide
Want more than the summary?
Get our free research guide, or tell us about your practice and we’ll get back to you.